1. Dellinger RP, Carlet J, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM for the Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
3. United States Food and Drug Administration Anti-Infective Drugs Advisory Committee (2001) Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, bla 125029/0. FDA briefing information.http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1.htm (accessed 14 July 2005)
4. United States Food and Drug Administration (2001) FDA clinical review drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, bla 125029/0, approved 21 November 2001.http://www.fda.gov/cder/biologics/review/droteli112101r1.htm (accessed 14 July 2005)
5. Lilly (n.d.) Association of Xigris (drotrecogin alfa activated) with mortality in patients with single organ dysfunction and recent surgery: ADDRESS study (letter).http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/xigris_nth_e.html (accessed 14 July 2005)